|
1
|
Dohner H, Estey EH, Amadori S, Appelbaum
FR, Buchner T, Burnett AK, et al: Diagnosis and management of acute
myeloid leukemia in adults: recommendations from an international
expert panel, on behalf of the European LeukemiaNet. Blood.
115:453–474. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhou GB, Zhang J, Wang ZY, Chen SJ and
Chen Z: Treatment of acute promyelocytic leukaemia with all-trans
retinoic acid and arsenic trioxide: a paradigm of synergistic
molecular targeting therapy. Philos Trans R Soc of Lond B Biol Sci.
362:959–971. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
West KA, Castillo SS and Dennis PA:
Activation of the PI3K/Akt pathway and chemotherapeutic resistance.
Drug Resist Updat. 5:234–248. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Franke TF, Hornik CP, Segev L, Shostak GA
and Sugimoto C: PI3K/Akt and apoptosis: size matters. Oncogene.
22:8983–8998. 2003. View Article : Google Scholar
|
|
5
|
Xu Q, Simpson SE, Scialla TJ, Bagg A and
Carroll M: Survival of acute myeloid leukemia cells requires PI3
kinase activation. Blood. 102:972–980. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tamburini J, Chapuis N, Bardet V, et al:
Mammalian target of rapamycin (mTOR) inhibition activates
phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like
growth factor-1 receptor signaling in acute myeloid leukemia:
rationale for therapeutic inhibition of both pathways. Blood.
111:379–382. 2008. View Article : Google Scholar
|
|
7
|
Zeng Z, Shi YX, Tsao T, et al: Targeting
of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in
AML cells under conditions mimicking the bone marrow
microenvironment. Blood. 120:2679–2689. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shrimali D, Shanmugam MK, Kumar AP, et al:
Targeted abrogation of diverse signal transduction cascades by
emodin for the treatment of inflammatory disorders and cancer.
Cancer Lett. 341:139–149. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu L, Cai B, Zheng S, Liu X, Cai H and Li
H: Effect of emodin on endoplasmic reticulum stress in rats with
severe acute pancreatitis. Inflammation. 36:1020–1029. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
de Tamokou JD, Chouna JR, Fischer-Fodor E,
et al: Anticancer and antimicrobial activities of some
antioxidant-rich Cameroonian medicinal plants. PloS One.
8:e558802013.PubMed/NCBI
|
|
11
|
Zhang L, Lau YK, Xia W, Hortobagyi GN and
Hung MC: Tyrosine kinase inhibitor emodin suppresses growth of
HER-2/neu-overexpressing breast cancer cells in athymic mice and
sensitizes these cells to the inhibitory effect of paclitaxel. Clin
Cancer Res. 5:343–353. 1999.
|
|
12
|
Brown M, Bellon M and Nicot C: Emodin and
DHA potently increase arsenic trioxide interferon-alpha-induced
cell death of HTLV-I-transformed cells by generation of reactive
oxygen species and inhibition of Akt and AP-1. Blood.
109:1653–1659. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wei WT, Chen H, Ni ZL, et al: Antitumor
and apoptosis-promoting properties of emodin, an anthraquinone
derivative from Rheum officinale Baill, against pancreatic
cancer in mice via inhibition of Akt activation. Int J Oncol.
39:1381–1390. 2011.PubMed/NCBI
|
|
14
|
Huang LY, Hu JD, Chen XJ, Zhu LF and Hu
HL: Effects of emodin on the proliferation inhibition and apoptosis
induction in HL-60 cells and the involvement of c-myc gene.
Zhonghua Xue Ye Xue Za Zhi. 26:348–351. 2005.PubMed/NCBI
|
|
15
|
Chen YY, Zheng HY, Hu JD, et al:
Inhibitory effects of emodin on drug-resistant HL-60/ADR cell
proliferation and its induction of apoptosis. Zhongguo Shi Yan Xue
Ye Xue Za Zhi. 15:955–960. 2007.PubMed/NCBI
|
|
16
|
Chen YY, Li J, Hu JD, et al: Reversing
effects of emodin on multidrug resistance in resistant HL-60/ADR
cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 21:1413–1422.
2013.PubMed/NCBI
|
|
17
|
Lin M, Hu J, Liu T, Li J, Chen B and Chen
X: Knockdown of nucleophosmin by RNA interference reverses
multidrug resistance in resistant leukemic HL-60 cells.
Immunobiology. 218:1147–1154. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hu J, Lin M, Liu T, Li J, Chen B and Chen
Y: DIGE-based proteomic analysis identifies nucleophosmin/B23 and
nucleolin C23 as over-expressed proteins in relapsed/refractory
acute leukemia. Leuk Res. 35:1087–1092. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tamburini J, Elie C, Bardet V, et al:
Constitutive phosphoinositide 3-kinase/Akt activation represents a
favorable prognostic factor in de novo acute myelogenous leukemia
patients. Blood. 110:1025–1028. 2007. View Article : Google Scholar
|
|
20
|
Martelli AM, Evangelisti C, Chiarini F and
McCubrey JA: The phosphatidylinositol 3-kinase/Akt/mTOR signaling
network as a therapeutic target in acute myelogenous leukemia
patients. Oncotarget. 1:89–103. 2010.PubMed/NCBI
|
|
21
|
Grandage VL, Gale RE, Linch DC and Khwaja
A: PI3-kinase/Akt is constitutively active in primary acute myeloid
leukaemia cells and regulates survival and chemoresistance via
NF-kappaB, Mapkinase and p53 pathways. Leukemia. 19:586–594.
2005.PubMed/NCBI
|
|
22
|
Niu C, Yan H, Yu T, et al: Studies on
treatment of acute promyelocytic leukemia with arsenic trioxide:
remission induction, follow-up, and molecular monitoring in 11
newly diagnosed and 47 relapsed acute promyelocytic leukemia
patients. Blood. 94:3315–3324. 1999.
|
|
23
|
Mathews V, George B, Chendamarai E, et al:
Single-agent arsenic trioxide in the treatment of newly diagnosed
acute promyelocytic leukemia: long-term follow-up data. J Clin
Oncol. 28:3866–3871. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ghavamzadeh A, Alimoghaddam K, Rostami S,
et al: Phase II study of single-agent arsenic trioxide for the
front-line therapy of acute promyelocytic leukemia. J Clin Oncol.
29:2753–2757. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ma YN, Chen MT, Wu ZK, et al: Emodin can
induce K562 cells to erythroid differentiation and improve the
expression of globin genes. Mol Cell Biochem. 382:127–136. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Muto A, Hori M, Sasaki Y, et al: Emodin
has a cytotoxic activity against human multiple myeloma as a
Janus-activated kinase 2 inhibitor. Mol Cancer Ther. 6:987–994.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yan Y, Su X, Liang Y, et al: Emodin azide
methyl anthraquinone derivative triggers mitochondrial-dependent
cell apoptosis involving in caspase-8-mediated Bid cleavage. Mol
Cancer Ther. 7:1688–1697. 2008. View Article : Google Scholar
|
|
28
|
Tauchi T, Sumi M, Nakajima A, Sashida G,
Shimamoto T and Ohyashiki K: BCL-2 antisense oligonucleotide
genasense is active against imatinib-resistant BCR-ABL-positive
cells. Clin Cancer Res. 9:4267–4273. 2003.PubMed/NCBI
|
|
29
|
Kim R, Emi M, Tanabe K and Toge T:
Preclinical evaluation of antisense bcl-2 as a chemosensitizer for
patients with gastric carcinoma. Cancer. 101:2177–2186. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Karnak D and Xu L: Chemosensitization of
prostate cancer by modulating Bcl-2 family proteins. Current Drug
Targets. 11:699–707. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Parrondo R, de Las Pozas A, Reiner T and
Perez-Stable C: ABT-737, a small molecule Bcl-2/Bcl-xL antagonist,
increases antimitotic-mediated apoptosis in human prostate cancer
cells. PeerJ. 1:e1442013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nasr R, Guillemin MC, Ferhi O, et al:
Eradication of acute promyelocytic leukemia-initiating cells
through PML-RARA degradation. Nat Med. 14:1333–1342. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hu J, Liu YF, Wu CF, et al: Long-term
efficacy and safety of all-trans retinoic acid/arsenic
trioxide-based therapy in newly diagnosed acute promyelocytic
leukemia. Proc Natl Acad Sci USA. 106:3342–3347. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Isakson P, Bjoras M, Boe SO and Simonsen
A: Autophagy contributes to therapy-induced degradation of the
PML/RARA oncoprotein. Blood. 116:2324–2331. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang XW, Yan XJ, Zhou ZR, et al: Arsenic
trioxide controls the fate of the PML-RARalpha oncoprotein by
directly binding PML. Science. 328:240–243. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Harris MN, Ozpolat B, Abdi F, et al:
Comparative proteomic analysis of all-trans-retinoic acid treatment
reveals systematic posttranscriptional control mechanisms in acute
promyelocytic leukemia. Blood. 104:1314–1323. 2004. View Article : Google Scholar
|
|
37
|
Bayascas JR and Alessi DR: Regulation of
Akt/PKB Ser473 phosphorylation. Mol Cell. 18:143–145. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sarbassov DD, Guertin DA, Ali SM and
Sabatini DM: Phosphorylation and regulation of Akt/PKB by the
rictor-mTOR complex. Science. 307:1098–1101. 2005. View Article : Google Scholar : PubMed/NCBI
|
